var data={"title":"Tazarotene: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tazarotene: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7011?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">see &quot;Tazarotene: Drug information&quot;</a> and <a href=\"topic.htm?path=tazarotene-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tazarotene: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224840\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Avage;</li>\n      <li>Fabior;</li>\n      <li>Tazorac</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224841\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tazorac</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050155\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Acne Products</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Keratolytic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050148\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">see &quot;Tazarotene: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored or reduce dosing to an interval the patient is able to tolerate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne vulgaris:</b> Children &ge;12 years and Adolescents: Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream or gel: Tazorac (0.1%): Apply as a thin film (2 mg/cm<sup>2</sup>) to affected areas once daily in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Fabior (0.1%): Apply a small amount to affected area once daily in the evening.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis:</b>  Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream: Adolescents &ge;18 years: Tazorac (0.05%): Initial: Apply a thin film (2 mg/cm<sup>2</sup>) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel: Children &ge;12 years and Adolescents: Tazorac (0.05%): Initial: Apply a thin film (2 mg/cm<sup>2</sup>) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary; apply to no more than 20% of the body surface area</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:</b> Adolescents &ge;17 years: Topical: Cream: Avage (0.1%): Apply a pea-sized amount once daily at bedtime; lightly cover entire face including eyelids if desired</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne vulgaris:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream or gel: Tazorac (0.1%): Apply as a thin film (2 mg/cm<sup>2</sup>) to affected areas once daily in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Fabior (0.1%): Apply a small amount to affected area once daily in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream: Tazorac (0.05%): Initial: Apply a thin film (2 mg/cm<sup>2</sup>) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel: Tazorac (0.05%): Initial: Apply a thin film (2 mg/cm<sup>2</sup>) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary; apply to no more than 20% of the body surface area</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:</b> Topical: Avage (0.1%): Apply a pea-sized amount once daily at bedtime; lightly cover entire face including eyelids if desired</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224820\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avage: 0.1% (30 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazorac: 0.05% (30 g, 60 g); 0.1% (30 g, 60 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Foam, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fabior: 0.1% (50 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazorac: 0.05% (30 g, 100 g); 0.1% (30 g, 100 g) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224805\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050158\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For external use only; avoid contact with eyes and mouth; also avoid contact with the eyelids when used for acne or psoriasis. Do not apply to eczematous, abraded, broken, or sunburned skin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acne:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream (Tazorac), foam, gel: Apply in evening after gently cleansing and drying face; apply enough to cover entire affected area.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Foam: Wash with a mild cleanser and dry affected area before applying foam. Shake can before use then dispense a small amount of foam into palm of the hand. Use fingertips to lightly cover the entire affected area of the face and/or upper trunk with a thin layer; massage into skin until foam disappears. Wash hands after use. Moisturizer may be used if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines: Cream (Avage): Apply to clean, dry face at bedtime; lightly cover entire face including eyelids if desired. Emollients or moisturizers may be applied before or after; if applied before tazarotene, ensure cream or lotion has absorbed into the skin and has dried completely before applying tazarotene.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Psoriasis: Cream (Tazorac), gel: Apply in evening. If a bath or shower is taken prior to application, dry the skin before applying. If emollients are used, apply them at least 1 hour prior to application. Unaffected skin may be more susceptible to irritation; avoid application to these areas.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224837\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: Store at 25&deg;C (77&deg;F); excursions are permitted between -5&deg;C to 30&deg;C (23&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store upright and protect from freezing. Foam is flammable; avoid fire, flame, or smoking during and immediately following application. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 49&deg;C (120&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050157\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: Treatment of acne vulgaris (Tazorac [0.1%]: FDA approved in ages &ge;12 years and adults); treatment of plaque psoriasis (Tazorac [0.05% and 0.1%]: FDA approved in ages &ge;18 years and adults); mitigation (palliation) of facial skin wrinkling, facial mottled hyper-/hypopigmentation, and benign facial lentigines as adjunct to comprehensive skin care and sunlight avoidance (Avage [0.1%]: FDA approved in ages &ge;17 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Treatment of acne vulgaris (Fabior [0.1%]: FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel: Treatment of mild to moderate facial acne vulgaris (Tazorac [0.1%]: FDA approved in ages &ge;12 years and adults); treatment of stable plaque psoriasis of up to 20% body surface area involvement (Tazorac [0.05% and 0.1%]: FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224867\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Burning sensation of skin, cheilitis, contact dermatitis, dermatitis, desquamation, eczema, erythema, exacerbation of psoriasis, pruritus, skin discoloration, skin fissure, skin irritation, skin pain, skin photosensitivity, skin rash, stinging of the skin, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypertriglyceridemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction, local hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site pain, local hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Ocular irritation (including edema, irritation, and inflammation of the eye or eyelid)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Application site edema, exfoliation of skin, impetigo, pain, skin blister</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224826\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to tazarotene or any component of the formulation; women who are or may become pregnant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for retinoids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224809\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: May cause photosensitivity; exposure to ultraviolet rays (including sunlight/sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized. Risk may be increased by concurrent therapy with known photosensitizers (thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides); avoid coadministration. Use with caution in patients with a personal or family history of skin cancer. Daily sunscreen use and other protective measures recommended. Patients with sunburn should discontinue use until sunburn has healed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin irritation: Local tolerability reactions (including blistering or skin desquamation) or local hypersensitivity reactions (including urticaria) may occur; excessive burning, pruritus, peeling, and skin redness may occur, especially during the early weeks of treatment. Treatment can increase skin sensitivity to weather extremes of wind or cold. Concomitant topical medications (eg, medicated or abrasive soaps, cleansers, or cosmetics with a strong drying effect) should be avoided due to increased skin irritation. Reduce frequency or discontinue use until irritation disappears.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women of childbearing potential: Consider the possibility of pregnancy prior to initiation of therapy; a negative pregnancy test should be obtained within 2 weeks prior to treatment and treatment should begin during a normal menstrual period. Must use adequate contraceptive measures to avoid pregnancy during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Foam: Propellant is flammable; avoid fire and smoking during and immediately after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gel: Safety and efficacy of gel applied over &gt;20% of BSA have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For external use only; avoid contact with eyes, eyelids, and mouth. Not for use on eczematous, abraded, broken, or sunburned skin; not for treatment of lentigo maligna. Avoid application over extensive areas. The efficacy of tazarotene gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300105\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224814\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13004&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224828\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use in pregnancy is contraindicated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events have been observed in animal reproduction studies. A negative pregnancy test should be obtained within 2 weeks prior to treatment; treatment should begin during a normal menstrual period.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050154\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Disease severity in plaque psoriasis (reduction in erythema, scaling, induration); pregnancy test prior to treatment of females of childbearing age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224808\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic, acetylenic retinoid which modulates differentiation and proliferation of epithelial tissue and exerts some degree of anti-inflammatory and immunological activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224825\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Psoriasis: 1 week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Therapeutic: Psoriasis: Effects have been observed for up to 3 months after a 3-month course of topical treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Minimal following cutaneous application (&le;6% of dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Retained in skin for prolonged periods after topical application</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99% (tazarotenic acid)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Prodrug, rapidly metabolized via esterase hydrolysis to an active metabolite (tazarotenic acid) following topical application and systemic absorption; tazarotenic acid undergoes further hepatic metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream, gel: ~18 hours (tazarotenic acid)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Foam: 8.1 &plusmn; 3.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine and feces (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224827\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Avage External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (30 g): $464.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Tazarotene External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (30 g): $390.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Tazorac External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 g): $446.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (30 g): $474.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Fabior External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (50 g): $543.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Tazorac External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 g): $446.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (30 g): $474.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224829\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aguder (CL);</li>\n      <li>Avage (NZ, SG);</li>\n      <li>Evitar (SA);</li>\n      <li>Ful Lee (TW);</li>\n      <li>Glentaz (VN);</li>\n      <li>Le Wei (CN);</li>\n      <li>Marzoten (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Psorix Gel (BD);</li>\n      <li>Pzoret (CO);</li>\n      <li>Que Wei (CN);</li>\n      <li>Rantric (CO);</li>\n      <li>Soritene (BD);</li>\n      <li>Sumaytene (TW);</li>\n      <li>Suretin (CH, IT, MX);</li>\n      <li>Tarac (TW);</li>\n      <li>Tazmeral (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tazoderm Forte (IN);</li>\n      <li>Tazorac (CZ);</li>\n      <li>Tazoskin (BD);</li>\n      <li>Tazoten (TW);</li>\n      <li>Tazret (PH);</li>\n      <li>Zaroten (BD);</li>\n      <li>Zorac (AT, AU, BE, BG, BR, DE, ES, FR, GB, GR, HR, IL, IT, LB, NZ, PL, SE);</li>\n      <li>Zorac Gel (IL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avage (tazarotene) [prescribing information]. Irvine, CA: Allergan, Inc; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fabior (tazarotene) [prescribing information]. Research Triangle Park, NC: Stiefel Laboratories, Inc; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tazorac cream (tazarotene) [prescribing information]. Irvine, CA: Allergan, Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tazorac gel (tazarotene) [prescribing information]. Irvine, CA: Allergan, Inc; May 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13004 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F224840\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F224841\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050155\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050148\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F224820\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F224805\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050158\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F224837\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050157\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F224867\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F224826\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F224809\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300105\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F224814\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F224828\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050154\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F224808\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F224825\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F224827\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F224829\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13004|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">Tazarotene: Drug information</a></li><li><a href=\"topic.htm?path=tazarotene-patient-drug-information\" class=\"drug drug_patient\">Tazarotene: Patient drug information</a></li></ul></div></div>","javascript":null}